Stockscreener 앱 받기
15.40
7.73%
-1.29
시간 외 거래:
15.90
0.50
+3.25%
전일 마감가:
$16.69
열려 있는:
$16.44
하루 거래량:
2.10M
Relative Volume:
0.91
시가총액:
$1.06B
수익:
$1.03B
순이익/손실:
$-94.55M
주가수익비율:
-10.99
EPS:
-1.4012
순현금흐름:
$-3.64M
1주 성능:
-5.11%
1개월 성능:
+20.12%
6개월 성능:
-31.31%
1년 성능:
-23.27%
1일 변동 폭
$15.33
$17.07
1주일 범위
$15.33
$17.20
52주 변동 폭
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
명칭
Tandem Diabetes Care Inc
전화
858-366-6900
주소
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
15.40 | 1.15B | 1.03B | -94.55M | -3.64M | -1.4012 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 업그레이드 | Truist | Hold → Buy |
| 2026-03-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | 업그레이드 | Lake Street | Hold → Buy |
| 2026-02-20 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-01-27 | 재개 | TD Cowen | Buy |
| 2025-12-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | 재개 | Stifel | Hold |
| 2025-09-08 | 개시 | Oppenheimer | Outperform |
| 2025-08-12 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-08-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-06-16 | 개시 | Truist | Hold |
| 2025-04-10 | 개시 | Mizuho | Neutral |
| 2025-03-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-03-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-10-04 | 개시 | Goldman | Neutral |
| 2024-10-02 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-08 | 개시 | Canaccord Genuity | Buy |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | 업그레이드 | Stifel | Hold → Buy |
| 2023-08-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-05-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-04-24 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-15 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-08-09 | 다운그레이드 | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Underweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | 개시 | Wells Fargo | Overweight |
| 2020-07-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-18 | 재확인 | Raymond James | Outperform |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-06 | 개시 | Raymond James | Outperform |
| 2020-02-04 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | 개시 | Guggenheim | Buy |
| 2019-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2019-05-17 | 재확인 | BofA/Merrill | Neutral |
| 2019-05-13 | 개시 | SVB Leerink | Outperform |
| 2019-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2019-03-05 | 재확인 | BofA/Merrill | Neutral |
| 2019-02-27 | 재확인 | Lake Street | Buy |
| 2018-11-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | 재확인 | Dougherty & Company | Buy |
| 2018-09-26 | 재확인 | Piper Jaffray | Overweight |
모두보기
Tandem Diabetes Care Inc 주식(TNDM)의 최신 뉴스
Tandem Diabetes Care Q1 earnings call highlights - MSN
Tandem insulin pumps cleared in EU for expanded indications - MSN
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up - Eastern Progress
Tandem Diabetes Care Inc (TNDM) Shares Surge 5.1% -- What GF Sco - GuruFocus
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Why Insulet thinks its fully closed loop system will stand apart from rivals - MedTech Dive
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25 - Moomoo
TNDM: Momentum builds with pharmacy transition, Mobi Tubeless launch, and international expansion - TradingView
Tandem Diabetes Care Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
3 takeaways from ADA - MedTech Dive
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy - BioSpace
How The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst Targets - Yahoo Finance
Wall Street analysts see a 56.2% upside in Tandem Diabetes Care (TNDM): Can the stock really move this high? - MSN
Technical Reactions to TNDM Trends in Macro Strategies - Stock Traders Daily
Tandem Diabetes (TNDM) Secures CE Mark for Expanded Use of Insul - GuruFocus
Tandem Diabetes’ Insulin Pumps Win EU Nods for T2D, T1D in Pregnancy - Medical Product Outsourcing
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High? - Yahoo Finance
Tandem Diabetes receives CE mark for expanded insulin pump uses By Investing.com - Investing.com Nigeria
Tandem Diabetes receives CE mark for expanded insulin pump uses - Investing.com
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Diabetes tech companies are racing toward ‘fully closed loop’ devices. But automation comes with trade-offs. - MedTech Dive
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now - Yahoo Finance
Tandem: Upgrading To Hold On A High-Stakes Pivot Story - Seeking Alpha
Tandem Diabetes Valuation: Is 1.1x Sales a Buy? - Yahoo Finance
Wells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump Shift - Yahoo Finance
Tandem Diabetes Care Hits Day High with 11.16% Surge in Stock Price - Markets Mojo
Tandem Diabetes Care (TNDM) CEO receives 191,103 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes Care (TNDM) EVP awarded 29,136 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes (TNDM) CFO receives 62,657 restricted stock unit award - Stock Titan
29,136 RSUs granted to Tandem Diabetes Care (TNDM) chief operating officer - Stock Titan
Tandem Diabetes Care (TNDM) EVP receives 29,136 RSU equity award - Stock Titan
Tandem Diabetes Care (TNDM) CTO awarded 26,003 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes Care (TNDM) awards 29,136 RSUs to EVP & Chief Legal Officer - Stock Titan
TNDM Stock: What to Know About Tandem's 2026 Reset - TradingView
Why Is Tandem Diabetes (TNDM) Stock Soaring Today - Yahoo Finance
Why is Tandem Diabetes Care stock surging today? By Investing.com - Investing.com Canada
TNDM Upgraded by Wells Fargo -- Price Target Raised to $27 - GuruFocus
Tandem Diabetes (TNDM) Receives Upgrade from Wells Fargo - GuruFocus
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Adjusts Price Target to $27 From $21 - marketscreener.com
Tandem Diabetes Care Hits Day High with 12.82% Surge in Stock Price - Markets Mojo
Wells Fargo upgrades Tandem Diabetes stock rating on pharmacy outlook By Investing.com - Investing.com Canada
TNDM stock down following Q1 earnings & revenue beat, gross margin up - MSN
What Does Tandem Diabetes Care's Upsized Convertible Note Offering Mean for Investors - Kavout
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $17 - Moomoo
TNDM Maintained by Citigroup -- Price Target Lowered to $17 - GuruFocus
Tandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Sc - GuruFocus
Q1 2025 Tandem Diabetes Care Inc Earnings Call Transcript - GuruFocus
Tandem Diabetes Care Inc (TNDM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tandem Diabetes Care Inc 주식 (TNDM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Howell Peyton R | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
29,836 |
| Malagueira Joao Paulo Falcao | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
22,458 |
| Sodhi Rajwant | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
24,280 |
| McGroddy-Goetz Kathleen | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
26,612 |
| ROBERTSON REBECCA B | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
22,542 |
| TWOMEY CHRISTOPHER J | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
24,434 |
| Cha Myoungil | Director |
May 21 '26 |
Option Exercise |
0.00 |
8,759 |
0 |
22,458 |
2.43%
자본화:
|
볼륨(24시간):